Browsing by Author "Tadokoro, Hakaru"
Now showing 1 - 10 of 12
Results Per Page
Sort Options
- A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarkerPublication . Aguiar, Pedro N., Jr.; Santoro, Ilka Lopes; Tadokoro, Hakaru; Lopes, Gilberto de Lima; Filardi, Bruno Andraus; Oliveira, Pedro; Castelo-Branco, Pedro; Mountzios, Giannis; de Mello, Ramon AndradeBackground: Recent studies with nivolumab (a monoclonal antibody against programmed cell death 1 [PD-1] receptor) have shown promise non-small-cell lung cancer (NSCLC) treatment. Methods: To review available clinical trials data in order to assess nivolumab efficacy and the role of tumoral PDL-1 expression as a biomarker. Results: Nine eligible studies included 2102 patients. In the second line setting, nivolumab achieved a 1-year survival rate of 41%; and in the first line, a 1-year survival rate of 76%. For those with PD-L1 expression <1%, nivolumab showed a trend for improved survival compared with docetaxel. Conclusions: The available data reinforce nivolumab activity against NSCLC in first-line or subsequent lines. Although PD-L1 expression is related to greater response, PD-L1 negative patients had also some benefit.
- An estimate of the economic impact of immunotherapy relative to PD-L1 expression in Brazil - An update with brazilian costsPublication . Aguiar, Pedro, Jr.; De Mello, Ramon Andrade; Tadokoro, Hakaru; Babiker, Hani; Lopes, GilbertoDelivering high quality cancer care at an affordable cost is one of the main challenges for health care professionals and policy makers, especially in lowand middle-income countries. The objective of our study is to assess the economic impact of nivolumab and pembrolizumab with and without the use of PD-L1 as a biomarker in Brazil.
- Anti-EGFR monoclonal antibodies plus chemotherapy in the first-line treatment of advanced NSCLC: a meta-analysisPublication . Stock, Gustavo; Aguiar, Pedro, Jr.; Santoro, Ilka; Tadokoro, Hakaru; De Mello, Ramon Andrade; Lopes, Gilberto
- Comparative cost-effectiveness analysis of avelumab plus axitinib versus pembrolizumab plus axitinib, ipilimumab plus nivolumab, and sunitnib for advanced renal cell carcinoma in the UK perspectivePublication . De Mello, Ramon Andrade; Ayoub, Emili; Castelo-Branco, Pedro; De Almeida Zia, Victor Andre; Savio, Andre; Pozza, Daniel Humberto; Tadokoro, Hakaru; Teich, Nelson
- Comparative Outcome Assessment of EGFR TKIs for the Treatment of Advanced Non-Small-Cell Lung Cancer: A Network Meta-AnalysisPublication . De Mello, Ramon Andrade; Aguiar, Pedro, Jr.; Cabral, Paloma; Chaves, Fablo; Liu, Davi; Soares, João Paulo; Mountzios, Giannis; Tadokoro, Hakaru; Lopes, Gilberto de Lima
- Current advances in targeted therapies for metastatic gastric cancer: improving patient carePublication . Aguiar, Pedro Nazareth Jr.; Muniz, Thiago Pimentel; Miranda, Raelson Rodrigues; Tadokoro, Hakaru; Forones, Nora Manoukian; Monteiro, Inês-de-Paula; Castelo-Branco, Pedro; Janjigian, Yelena Y.; Mello, Ramon Andrade deIn this article, we review the literature on the current advances in targeted therapies for metastatic gastric cancer aimed at improving patient care. We conclude that the key to guiding targeted therapy is individual biomarkers, which are not completely elucidated. HER2 overexpression is the only predictive biomarker currently in use. Furthermore, it is necessary to understand that gastric tumors are heterogeneous; therefore, is impossible to evaluate a novel biological compound without evaluating personal biomarkers. The selection of patients who are able to receive each treatment is paramount for improving advanced gastric cancer survival and reducing unnecessary costs.
- EGFR and EML4-ALK updated therapies in non-small cell lung cancer.Publication . Mello, Ramon Andrade de; Liu, Davi J J; Aguiar, Pedro N; Tadokoro, HakaruBACKGROUND: Non-small cell lung cancer is the leading cancer-related cause of death.OBJECTIVE: We review the latest therapies for NSCLC with EGFR and ELM4-ALK mutations as well as the most relevant studies and promising patents.METHOD: A literature search of PubMed database was carried out to identify recent Clinical Trials using EGFR therapies and novel patents involving diagnosis and therapies on NSCLC. We conducted a search to find new therapy strategies, new biomarkers, and selected five patents we find relevant.RESULTS: Over the last few years, identification of cancer harboring epidermal growth factor receptor mutations (EGFR) or chromosomal rearrangements of anaplastic lymphoma kinase (ALK) led to new ways in classifying and treating NSCLC. On the other hand, acquired resistance are a constantly challenge in the management of patients with these mutations and new drugs options are in development to improve and amplify treatment strategies.CONCLUSIONS: Currently, EGFR TKIs (e.g.: erlotinib, gefitinib, osimertinib) and ALK inhibitors (crizotinib, ceritinib, alectinib) provided a new face for advanced NSCLC outcomes. To understand the disease molecular profile is mandatory to define the best approach for each patient.
- Estimate of economic impact of immune checkpoint inhibitors for NSCLC relative to PD-L1 expression in the USPublication . Aguiar, Pedro, Jr.; De Mello, Ramon Andrade; Tadokoro, Hakaru; Babiker, Hani; Gutierres, Barbara; Lopes, Gilberto
- Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targetsPublication . Aguiar, Pedro Nazareth; De Mello, Ramon Andrade; Noia Barreto, Carmelia Maria; Perry, Luke Alastair; Penny-Dimri, Jahan; Tadokoro, Hakaru; Lopes, Gilberto de LimaLung cancer is the leading cause of cancer-related deaths in the world. Immune checkpoint inhibitors (ICI) stimulate cytotoxic lymphocyte activity against tumour cells. These agents are available for the treatment of nonsmall cell lung cancer (NSCLC) after failure of platinumbased therapy. One recent study has demonstrated that ICI monotherapy was superior to platinum-based chemotherapy for first-line treatment. Nevertheless, this benefit was only for a minority of the population (30%) whose tumour programmed death receptor ligand-1 (PD-L1) expression was above 50%. Therefore, several strategies are under investigation. One option for patients with PD-L1 expression lower than 50% may be the combination of ICI with platinum-based chemotherapy or with ICIs against different targets. However, all of these combinations are at an early stage of investigation and may be very expensive or toxic, producing several harmful adverse events.
- New target therapies in advanced non-small cell lung cancer: a review of the literature and future perspectivesPublication . De Mello, Ramon Andrade; Neves, Nathália Moisés; Tadokoro, Hakaru; Amaral, Giovanna Araújo; Castelo-Branco, Pedro; Zia, Victor André de AlmeidaLung cancer (LC) is the most common neoplasm worldwide, and 85% of these tumors are classified as non-small cell lung cancer (NSCLC). LC treatment was initially restricted to cytotoxic chemotherapy-platinum compounds associated with 3rd generation cytotoxic agents (paclitaxel, gemcitabine, pemetrexed) and, more recently, with monoclonal antibodies (bevacizumab, ramucirumab). Advancements in treatment are correlated with prolonged overall survival (OS). Current advances are focused on target therapies. Target agents: Anti-epidermal growth factor receptor (EGFR) therapy consists of 1st and 2nd generation tyrosine kinase inhibitors (TKIs such as erlotinib, afatinib). In 60% of cases, resistance to these TKIs occurs due to T790M mutation in EGFR, which is overcome 3rd generation drugs (osimertinib). Anaplastic lymphoma kinase (ALK) is the target for drugs such as crizotinib, alectinib, ceritinib. Programmed death 1 (PD-1) and its ligand serve as targets for immunotherapy agents such as pembrolizumab, nivolumab, atezolizumab.